Houston, June 10th, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines and rare diseases, will be sharing key strategies for pharmaceutical companies needing to transition studies to a different CRO in a free webinar on June 18.
Houston, April 3rd, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, has been named a winner in Life Science Leader magazine’s 2019 CRO Leadership Awards. Pharm-Olam was rated highly by small pharma survey respondents, as well as all survey respondents combined, for delivering excellent clinical research services in Compatibility, Quality, and Reliability core award categories.
As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist
Houston, March 6, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines, and rare diseases, is marking its 25th anniversary with several announcements. These include an update to its rare disease service tier, progress on its transition to the Medidata Cloud platform, and ongoing global expansion. With record sales in 2018, these changes position Pharm-Olam for continued growth into 2019.
Houston, Feb. 5, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the treatment of short bowel syndrome (SBS).
Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.
CRO accelerates the delivery of life-changing therapies with a single view of data for all clinical trial stakeholders
HOUSTON, Tx. — April 26, 2018. Pharm-Olam International, a global, full-service Contract Research Organization (CRO) specializing in Oncology, Infectious Diseases & Vaccines, Rare Diseases and Pediatric indications, is prepared for the implementation of the European Union’s (EU’s) General Data Protection Regulation (GDPR), which will impact our industry among others where organizations collect and hold personal data on EU citizens. Utilizing Pharm-Olam’s version of the Bow Tie Methodology for visual risk assessment and management, powered by Ideagen’s Q-Pulse software, Pharm-Olam is fully prepared for the global GDPR roll-out. In anticipation of GDPR’s effective date (May 25, 2018), Pharm-Olam will be hosting an interactive 60-minute live training webinar on May 15, 2018 at 11a.m. EST for its pharmaceutical and biotechnology partners and clients. Registration and attendance is open to the public.